TechNavio today published its report Global Hemophilia Treatment Market 2010“2014. The report aids decision makers™ understanding of the present and the future landscape of the market.
Commenting on the report, an analyst from TechNavio™s Healthcare team said, A key driver for the growth of this market is various government comprehensive care programs running for the treatment of hemophilia. These programs aim to provide improved health, decreased hospitalization accompanied by decreased costs of care. Moreover, vendors are also supporting such comprehensive care programs in the form of campaigns. For instance, Novo Nordisk supports the “It’s Time for a Cure campaign among various other programs for the bleeding disorders community.
According to the report, mergers and acquisitions has become the core growth strategy for many healthcare vendors. It has become the growth avenue for product expansion, competitive advantage, and greater market share. The Global Hemophilia Treatment market is also witnessing a similar trend of strategic alliance for increasing the market share and global presence. For instance, in 2010, Baxter entered into a definitive agreement to acquire all the hemophilia-related assets of Archemix, a privately held biopharmaceutical company.
The report also discusses key challenges in this market including possible side effects of this form of treatment.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key players.
TechNavio, the market research platform of Infiniti Research Ltd, publishes periodic reports on niche and emerging technologies. For further information, please visit https://www.technavio.com/content/global-hemophilia-treatment-market-2010-2014
Follow us on Twitter @ Technavio
TechNavio Announces the Publication of its Report: Global Hemophilia Treatment Market 2010“2014
